News
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories (NYSE: ABT) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to
EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Inc. (NASDAQ: VKTX) has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.
[content-module:CompanyOverview|NYSE:JNJ]On the one hand, the company beat on the top and bottom lines and offered
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.
[content-module:CompanyOverview|NYSE:JNJ]On the one hand, the company beat on the top and bottom lines and offered
Sartorius Stock: Q1 Results Drive Strong Market Rally
Sartorius, the life science company, impressed investors with robust first-quarter 2025 performance, sending shares notably higher on Wednesday. Revenue increased by 7.7% to €883 million compared to
Sartorius Stock: Q1 Results Drive Strong Market Rally
Sartorius, the life science company, impressed investors with robust first-quarter 2025 performance, sending shares notably higher on Wednesday. Revenue increased by 7.7% to €883 million compared to
EQS-News: Starker Jahresauftakt: Sartorius erreicht im ersten Quartal deutlich profitables Wachstum
EQS-News: Starker Jahresauftakt: Sartorius erreicht im ersten Quartal deutlich profitables Wachstum
2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs
The medical sector stocks, notably the health insurance carriers, took a major drubbing in 2024 as Medicare Advantage (MA) plans continued to drive higher utilization costs, eating away at
Draegerwerk Stock: Q1 EBIT Plunges Despite Order Growth
Draegerwerk's first quarter 2025 results present a mixed picture for investors, with the medical and safety technology specialist reporting dramatically lower earnings despite record-breaking order
EQS-Adhoc: Carl Zeiss Meditec erzielt deutliche Gewinnsteigerung im zweiten Quartal 2024/25
EQS-Adhoc: Carl Zeiss Meditec erzielt deutliche Gewinnsteigerung im zweiten Quartal 2024/25
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz